Associations between urinary advanced glycation end products and cardiometabolic parameters in metabolically healthy obese women

Research output: Contribution to journalJournal articleResearchpeer-review

Documents

Estifanos Baye, Alicja Budek Mark, Malene Wibe Poulsen, Jeanette M Andersen, Lars Ove Dragsted, Susanne Gjedsted Bügel, Barbora de Courten

Advanced glycation end products (AGEs) have been implicated in the pathophysiology of type 2 diabetes and cardiovascular disease. We aimed to determine the associations of urinary carboxymethyl-lysine (CML) and methylglyoxal-hydroimidazolone (MG-H1) levels with cardiometabolic parameters in metabolically healthy obese women. Anthropometric, glycemic, cardiovascular, and urinary AGE parameters were measured in 58 metabolically healthy obese women (age: 39.98 ± 8.72 years; body mass index (BMI): 32.29 ± 4.05 kg/m2). Urinary CML levels were positively associated with BMI (r = 0.29, p = 0.02). After adjustment for age and BMI, there was a trend for positive associations between urinary CML levels and fasting (p = 0.06) and 2 h insulin (p = 0.05) levels, and insulin resistance measured by homeostatic model assessment (HOMA-IR) (p = 0.06). Urinary MG-H1 levels were positively associated with systolic and diastolic blood pressure, pulse pressure, mean arterial pressure, and total and low-density lipoprotein cholesterol after adjustment for age, BMI, and HOMA-IR (all p ˂ 0.05). There were no associations between urinary CML levels and cardiovascular parameters, and between urinary MG-H1 levels and glycemic measurements. Our data support a role of urinary AGEs in the pathophysiology of insulin resistance and cardiovascular disease; however, future studies are highly warranted.

Original languageEnglish
Article number1008
JournalJournal of Clinical Medicine
Volume8
Issue number7
Number of pages8
ISSN2077-0383
DOIs
Publication statusPublished - 2019

    Research areas

  • The Faculty of Science - Advanced glycation end products, Carboxymethyl-lysine, Methylglyoxal-derived hydroimidazolone, Insulin resistance, Type 2 diabetes, Cardiovascular disease

ID: 224947791